Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Müller-Tidow, Carsten  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Hernández-Malmierca P, Vonficht D, Schnell A, Uckelmann HJ, Bollhagen A, Mahmoud MAA, Landua S-L, van der Salm E, Trautmann CL, Raffel S, et al. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell. 2022;29(5):760-775.e10.
Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2022.
Neuendorff NRosa, Boshikova B, Frankenstein L, Kirchner M, Rohde C, Goldschmidt H, Frey N, Müller-Tidow C, Jordan K, Sauer S, et al. Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma. Front Oncol. 2023;13:1168120.
B
Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, et al. Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
C
Stelmach P, Richter S, Sauer S, Fabre MA, Gu M, Rohde C, Janssen M, Liebers N, Proynova R, Weinhold N, et al. Clonal hematopoiesis with and mutations impairs regeneration in autologous stem cell transplant recipients. Haematologica. 2023.
Beneyto-Calabuig S, Merbach AKathrin, Kniffka J-A, Antes M, Szu-Tu C, Rohde C, Waclawiczek A, Stelmach P, Gräßle S, Pervan P, et al. Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia. Cell Stem Cell. 2023.
Kriegsmann K, Wack M, Pavel P, Schmitt A, Kriegsmann M, Bruckner T, Müller-Tidow C, Wuchter P. Collection, cryostorage, transplantation and disposal of hematopoietic stem cell products. Biol Blood Marrow Transplant. 2018.
Waclawiczek A, Leppa A-M, Renders S, Stumpf K, Reyneri C, Betz B, Janssen M, Shahswar R, Donato E, Karpova D, et al. Combinatorial BCL-2 family expression in Acute Myeloid Leukemia Stem Cells predicts clinical response to Azacitidine/Venetoclax. Cancer Discov. 2023.
Schaffrath J, Diederichs T, Unverzagt S, Wass M, Gläser U, Weber T, Binder M, Müller-Tidow C, Müller LP. Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2021.
Kauer J, Sester LSophie, Kriegsmann K, Weinhold N, Ober M, Müller-Tidow C, Goldschmidt H, Raab M-S, Sauer S. Cyclophosphamide etoposide dexamethasone (CED) as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma. Hematol Oncol. 2023.
D
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HKathrin, Schwind S, Jentzsch M, Cross M, Kahl C, et al. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol. 2023.
E
Han H, Wang L, Ding Y, Neuber B, Hueckelhoven-Krauss AGabriele, Lin M, Yao H, Chen Q, Sauer T, Schubert M-L, et al. Extracorporeal photopheresis as a promising strategy for the treatment of GvHD after CAR-T cell therapy. Blood Adv. 2024.
F
Schuber M-L, Dietrich S, Stilgenbauer S, Schmitt A, Pavel P, Kunz A, Bondong A, Wegner M, Stadtherr P, Jung S, et al. Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Korell F, Schönland S, Schmitt A, Jansen M, Farid K, Müller-Tidow C, Dreger P, Schmitt M, Hegenbart U. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma. Biomark Res. 2023;11(1):91.
I
John L, Sauer S, Hegenbart U, Dreger P, Hundemer M, Müller-Tidow C, Schmitt A, Schmitt M, Raab MS, Schönland SO. Idecabtagene vicleucel is well tolerated and effective in relapsed/refractory myeloma patients with prior allogeneic stem cell transplantation. Transplant Cell Ther. 2023.
Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, Mikesch J-H, Krause S, Sauer T, et al. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience. Br J Cancer. 2023.
Radujkovic A, Kordelas L, Dai H, Schult D, Majer-Lauterbach J, Beelen D, Müller-Tidow C, Dreger P, Luft T. Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study. EBioMedicine. 2019.
L
Zhao D, Rohde C, Göllner S, Zhou F, Pauli C, Blank MFelix, Zinz R, Grab ALuise, Poos AM, John L, et al. The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations. Leukemia. 2023.
Bäumer N, Bäumer S, Haak M, Koschmieder S, Schönig K, Berdel WE, Müller-Tidow C. A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis. PLoS One. 2015;10(6):e0129147.
Sauer S, Erdmann K, Jensen AD, Wennmann M, Pavel P, Jordan K, Schmitt A, Kriegsmann M, Wuchter P, Goldschmidt H, et al. Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients. Transplant Cell Ther. 2021.
M
Bäumer N, Bäumer S, Berkenfeld F, Stehling M, Köhler G, Berdel WE, Müller-Tidow C, Tschanter P. Maintenance of Leukemia-Initiating Cells Is Regulated by the CDK Inhibitor Inca1. PLoS One. 2014;9(12):e115578.
N
Peramangalam PSona, Surapally S, Veltri AJ, Zheng S, Burns R, Zhu N, Rao S, Müller-Tidow C, Bushweller JH, Pulikkan JA. N-MYC regulates cell survival via eIF4G1 in inv(16) acute myeloid leukemia. Sci Adv. 2024;10(9):eadh8493.
P
Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer K-A, Lebiedz P, Görlich D, Gerth HU, et al. Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. PLoS One. 2016;11(8):e0160871.
Q
Jaramillo S, Le Cornet L, Kratzmann M, Krisam J, Görner M, Hänel M, Röllig C, Wass M, Scholl S, Ringhoffer M, et al. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD. Trials. 2023;24(1):591.
R
Katzerke C, Schaffrath J, Lützkendorf J, Janssen M, Merbach AKathrin, Nerger K, Binder M, Baum C, Lauer K, Rohde C, et al. Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome. Blood Adv. 2023.

Pages